Swedbank reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,786,834 shares of the biopharmaceutical company’s stock after selling 428,125 shares during the quarter. Swedbank owned about 0.14% of Gilead Sciences worth $144,769,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Penserra Capital Management LLC lifted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences in the second quarter worth $147,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV purchased a new stake in Gilead Sciences in the second quarter worth $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new stake in Gilead Sciences in the second quarter worth $172,000. Hedge funds and other institutional investors own 75.94% of the company’s stock.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the transaction, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock valued at $37,404,139 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.01 on Thursday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a market capitalization of $96,250.00, a PE ratio of 7.84, a P/E/G ratio of -1.26 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the previous year, the company posted $2.75 earnings per share. The company’s revenue was down 13.2% compared to the same quarter last year. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.81%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.66%.
COPYRIGHT VIOLATION NOTICE: “Swedbank Lowers Stake in Gilead Sciences, Inc. (GILD)” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/12/21/swedbank-lowers-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.